MT-125

• Description :

  MT-125 is a specific and well-tolerated inhibitor of non-muscle myosin IIA (Ki, NMIIA = 2.7 μM) and IIB (EC50 = 1.7 μM) . MT-125 can pass through the blood-brain barrier. MT-125 induces ferroptosis and DNA damage by increasing the levels of reactive oxygen species (ROS) within tumor cells. MT-125 can enhance the PDGFR signaling pathway. MT-125 can be used for research on glioblastoma[1].

• UNSPSC :

  12352005

• Target :

  Akt; ERK; Ferroptosis; mTOR; Myosin; PDGFR; Reactive Oxygen Species (ROS)

• Related Pathways :

  Apoptosis; Cytoskeleton; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer

• Smiles :

  CC1=CC2=C(N=C(N(C3=CC4=C(N=C(C)C=C4)C=C3)CC5)[C@]5(O)C2=O)C=C1.Cl

• Molecular Formula :

  C22H20ClN3O2

• Molecular Weight :

  393.87

• References & Citations :

  [1]Kenchappa RS, et al. MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma. Cell. 2025 Jun 3:S0092-8674 (25) 00569-0.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PDGFRα